glp 1 agonist liver disease Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty (NAFLD) and non-alcoholic steatohepatitis (NASH) GLP-1 Receptor Agonists as Treatments

2: Reduction in Certain Diseases Recent clinical trial results suggest that the health impacts of GLP-1RAs go beyond weight loss, with the drug leading to a reduction in various diseases, such as cardiovascular disease or slowing down the progression of some illnesses such as chronic kidney disease

Additionally, the loss of muscle mass has been problematic for some individuals taking this class of medication, with lean body mass accounting for up to 1540% of total weight loss

If using compounded semaglutide, verify your dose calculation using a peptide reconstitution calculator to ensure accuracy

Biotechnology Companies Risk

The shortage has created new access barriers for patients previously using or wishing to initiate these products for glycemic management, weight loss, and/or cardiovascular risk reduction